Cover Image
市場調查報告書

細胞間黏合分子1:開發中產品分析

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365735
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
細胞間黏合分子1:開發中產品分析 Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 44 Pages
簡介

本報告提供以細胞間黏合分子1為標的的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞發表。

簡介

  • 調查範圍

細胞間黏合分子1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀
  • 企業開發中的產品
  • 在大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Atlantic Healthcare Plc
  • China Medical System Holdings Ltd
  • RXi Pharmaceuticals Corp

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0941TDB

Summary:

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Intercellular Adhesion Molecule 1 (ICAM-1) is a protein encoded by the ICAM1 gene. It acts as a receptor for major receptor group rhinovirus A-B capsid proteins and Coxsackievirus A21 capsid proteins. ICAM1 promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation.

Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Gastrointestinal, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Inflammation, Arthritis, Atherosclerosis, Bleeding And Clotting Disorders, Cardiovascular Disease, Diabetic Retinopathy, Hepatocellular Carcinoma, Kidney Fibrosis, Liver Fibrosis, Pouchitis, Rheumatoid Arthritis, Skin Inflammation and Ulcerative Colitis.

The latest report Intercellular Adhesion Molecule 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
  • The report reviews Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Overview
    • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Companies Involved in Therapeutics Development
    • Atlantic Healthcare Plc
    • China Medical System Holdings Ltd
    • RXi Pharmaceuticals Corp
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Drug Profiles
    • alicaforsen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMS-024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DNP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EmstoPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MS-553 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Dormant Products
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Discontinued Products
  • Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2017: Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn's disease and Ulcerative Colitis
      • May 22, 2017: Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication
      • May 01, 2017: Atlantic Healthcare initiates FDA rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis
      • Apr 24, 2017: Atlantic Healthcare appoints Durbin as Nordic regions distributor of alicaforsen under the Named Patient Programme
      • Mar 22, 2017: Atlantic Healthcare announces Chairman to step down as company enters next phase of preparing for product commercialisation
      • Feb 28, 2017: Atlantic Healthcare confirms alicaforsen targets TLR-9, providing a second mechanism of action to treat new and existing inflammatory indications
      • Jan 24, 2017: Atlantic Healthcare receives FDA agreement to initiate rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis
      • Nov 07, 2016: Atlantic Healthcare granted U.S. patent extending IP cover of alicaforsen in the treatment of inflammatory bowel disease
      • Jun 30, 2016: Atlantic Healthcare progresses manufacturing arrangements for global supply of alicaforsen
      • May 26, 2016: Atlantic Healthcare Appoints New Commercial and Business Development Functions in U.S.
      • Feb 11, 2016: Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treat Inflammatory Bowel Disease Pouchitis
      • Jan 28, 2011: CMS Expects To Launch CMS024 For Treatment Of Primary Liver Carcinoma Three Years Ahead Of Plan In 2013
      • Jul 08, 2008: FDA Grants Orphan Drug Designation For Alicaforsen
      • Dec 02, 2004: Isis Pharmaceuticals Announces Phase 3 Clinical Trials Results Of Alicaforsen With Crohn's Disease
      • Dec 02, 2004: Isis Pharmaceuticals Inc. Announces Phase II clinical Trials Of Alicaforsen For Ulcerative Colitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Atlantic Healthcare Plc, H2 2017
  • Pipeline by China Medical System Holdings Ltd, H2 2017
  • Pipeline by RXi Pharmaceuticals Corp, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top